Entity

IMIDomics

Biotechnology - Therapeutics and Diagnostics

 

IMIDomics is an emerging global enterprise which combines exclusive access to data with biological insights that will lead to the discovery, targeting, and development of medicines for immune-mediated inflammatory diseases (IMID).

 

IMIDomics holds the exclusive commercial license to IMID clinical and epidemiological data collected by the Vall d’Hebron Hospital which powers an unparalleled understanding of IMID patient needs and experiences.

 

Robust, proprietary clinical data in combination with multiomics biomolecular data offers unique insights into disease mechanisms and patient condition, empowering therapeutic discovery.

934020503

elena.granell@imidomics.com

imidomics.com


Contact person: Elena Granell

Location: Ed. Clúster - 03D64